Abstract
Alzheimer disease (AD) is a common form of dementia affecting people older than the age of 65. Moreover, AD is commonly diagnosed by behavioural paradormants, cognitive tests, and is followed by brain scans. Computer Aided Diagnosis (CAD), applies medical imaging and machine learning algorithms, to aid in the early diagnosis of Alzheimer’s severity and advancement from prodromal stages i.e. Mild Cognitive Impairment (MCI) to diagnosed Alzheimer’s disease. In this work, SVM (support vector machine) is used for dementia stage classification. Anatomical structures of the brain were obtained from FreeSurfer’s processing of structural Magnetic Resonance Imaging (MRI) data and is utilized for as features for SVM. To be more precise, the system is processed using T1-weighted brain MRI datasets consisting of: 150 mild cognitive impairment (MCI) patients, 80 AD patients and 130 normal controls (NC) obtained from Alzheimer Disease Neuroimaging Initiative (ADNI) database. The volumes of brain structures (hippocampus, medial temporal lobe, whole brain, ventricular, cortical grey matter, entorhinal cortex and fusiform) are employed as biomarkers for multi-class classification of AD, MCI, and NC.
| Originalsprog | Engelsk |
|---|---|
| Titel | Advances in Signal Processing and Intelligent Recognition Systems : Proceedings of 3rd International Symposium on Signal Processing and Intelligent Recognition Systems, SIRS-2017 |
| Forlag | Springer |
| Publikationsdato | 2018 |
| Sider | 263-275 |
| ISBN (Trykt) | 9783319679334 |
| DOI | |
| Status | Udgivet - 2018 |
| Begivenhed | 3rd International Symposium on Signal Processing and Intelligent Recognition Systems, SIRS 2017 - Manipal, Indien Varighed: 13 sep. 2017 → 16 sep. 2017 |
Konference
| Konference | 3rd International Symposium on Signal Processing and Intelligent Recognition Systems, SIRS 2017 |
|---|---|
| Land/Område | Indien |
| By | Manipal |
| Periode | 13/09/2017 → 16/09/2017 |
| Navn | Advances in Intelligent Systems and Computing |
|---|---|
| Vol/bind | 678 |
| ISSN | 2194-5357 |
Finansiering
Acknowledgements. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS